Video

Dr. Atkins on the Efficacy of Dabrafenib/Trametinib in BRAF-Mutated Melanoma

Michael B. Atkins, MD, discusses the efficacy of dabrafenib plus trametinib in patients with BRAF-mutated melanoma.

Michael B. Atkins, MD, deputy director of the Georgetown Lombardi Comprehensive Cancer Center, and the Scholl Professor and vice chair of the Department of Medical Oncology at Georgetown University Medical Center, discusses the efficacy of dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF-mutated melanoma.

Initial results from the phase 3 COMBI-AD trial (NCT01682083) demonstrated that patients with stage IIIA-IIIC BRAF-mutant melanoma resected to no evidence of disease achieved a significant progression-free survival benefit with dabrafenib plus trametinib over placebo, Atkins says.

Most recently, in the 5-year updated results, which were presented at the 2020 ASCO Virtual Scientific Program, after a median follow-up of 60 months, there continued to be a 16% difference in relapse-free survival, favoring the combination of dabrafenib/trametinib, Atkins concludes.

Related Videos
Matthew P. Deek, MD
Thach-Giao Truong, MD
Benjamin Adam Weinberg, MD, associate professor, medicine, Georgetown Lombardi Comprehensive Cancer Center
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
Alexander C. Van Akkooi, MD, PhD, FRACS
Meredith McKean, MD
Ahmad Tarhini, MD, PhD
Ahmad Tarhini, MD, PhD
Georgina V. Long, MBBS, PhD, FRACP
Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center